PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27965580-0	2016	OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCdelta/p53.	OSU-2S	0-6	protein kinase C delta	Homo sapiens	97-105
27965580-0	2016	OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCdelta/p53.	OSU-2S	0-6	tumor protein p53	Homo sapiens	106-109
27965580-7	2016	The knockdown/over-expression of p53 was used to explain the differential sensitivity of HCC cell lines to sorafenib and/or OSU-2S.	OSU-2S	124-130	tumor protein p53	Homo sapiens	33-36
27965580-10	2016	In addition, PKCdelta knockdown abolished the synergy between sorafenib and OSU-2S.	OSU-2S	76-82	protein kinase C delta	Homo sapiens	13-21
27965580-12	2016	Conclusion: OSU-2S augments the anti-proliferative effect of sorafenib in HCC cell lines, in part, through the activation of PKCdelta.	OSU-2S	12-18	protein kinase C delta	Homo sapiens	125-133
27965580-13	2016	The p53 status in HCC cells predicts their sensitivity toward both sorafenib and OSU-2S.	OSU-2S	81-87	tumor protein p53	Homo sapiens	4-7
25937048-3	2015	OSU-2S increased the surface expression of CD74, a therapeutic antibody target in MCL cells.	OSU-2S	0-6	CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	Mus musculus	43-47
25937048-6	2015	The newly developed OSU-2S delivery using ROR1-directed immunonanoparticles provide selective targeting of OSU-2S to MCL and other ROR1(+) malignancies, sparing normal B cells.	OSU-2S	20-26	receptor tyrosine kinase-like orphan receptor 1	Mus musculus	42-46
25937048-6	2015	The newly developed OSU-2S delivery using ROR1-directed immunonanoparticles provide selective targeting of OSU-2S to MCL and other ROR1(+) malignancies, sparing normal B cells.	OSU-2S	20-26	receptor tyrosine kinase-like orphan receptor 1	Mus musculus	131-135
25937048-6	2015	The newly developed OSU-2S delivery using ROR1-directed immunonanoparticles provide selective targeting of OSU-2S to MCL and other ROR1(+) malignancies, sparing normal B cells.	OSU-2S	107-113	receptor tyrosine kinase-like orphan receptor 1	Mus musculus	42-46
25937048-6	2015	The newly developed OSU-2S delivery using ROR1-directed immunonanoparticles provide selective targeting of OSU-2S to MCL and other ROR1(+) malignancies, sparing normal B cells.	OSU-2S	107-113	receptor tyrosine kinase-like orphan receptor 1	Mus musculus	131-135
24947019-3	2015	OSU-2S induces activation of protein phosphatase 2A (PP2A), phosphorylation and nuclear translocation of SHP1(S591) and deregulation of multiple cellular processes in chronic lymphocytic leukemia (CLL) resulting in potent cytotoxicity.	OSU-2S	0-6	protein phosphatase 2 phosphatase activator	Homo sapiens	53-57
24947019-3	2015	OSU-2S induces activation of protein phosphatase 2A (PP2A), phosphorylation and nuclear translocation of SHP1(S591) and deregulation of multiple cellular processes in chronic lymphocytic leukemia (CLL) resulting in potent cytotoxicity.	OSU-2S	0-6	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	105-109
24947019-4	2015	To preclude OSU-2S-mediated effects on these ubiquitous phosphatases in unintended cells and avoid potential adverse effects, we developed an OSU-2S-targeted delivery of immunonanoparticles (2A2-OSU-2S-ILP), that mediated selective cytotoxicity of CLL but not normal B cells through targeting receptor tyrosine kinase ROR1 expressed in leukemic but not normal B cells.	OSU-2S	142-148	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	318-322
21391227-3	2011	This effort led to the development of OSU-2S, which exhibits higher potency than FTY720 in suppressing HCC cell growth through PKCdelta activation.	OSU-2S	38-44	protein kinase C, delta	Mus musculus	127-135
21391227-6	2011	Several lines of pharmacological and molecular genetic evidence indicate that ROS-PKCdelta-caspase-3 signaling underlies OSU-2S-mediated antitumor effects, and that differences in the antitumor activity between FTY720 and OSU-2S were attributable to SphK2-mediated phosphorylation of FTY720, which represents a metabolic inactivation of its antitumor activity.	OSU-2S	121-127	protein kinase C, delta	Mus musculus	82-90
21391227-6	2011	Several lines of pharmacological and molecular genetic evidence indicate that ROS-PKCdelta-caspase-3 signaling underlies OSU-2S-mediated antitumor effects, and that differences in the antitumor activity between FTY720 and OSU-2S were attributable to SphK2-mediated phosphorylation of FTY720, which represents a metabolic inactivation of its antitumor activity.	OSU-2S	121-127	sphingosine kinase 2	Mus musculus	250-255